Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Diagnostics › Molecular Diagnostics › Study Validates Oncotype DX AR-V7 Chemo Prediction

Study Validates Oncotype DX AR-V7 Chemo Prediction

Jun 28, 2018
|
staff reporter

NEW YORK (GenomeWeb) – A newly published  multi-institutional cohort study has validated Epic Sciences' circulating tumor cell-based AR-V7 test, now marketed by Genomic Health as Oncotype DX AR-V7 Nucleus Detect.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

What's Popular?

In Molecular Diagnostics

  1. President Biden Announces Plan to Expand SARS-CoV-2 Testing, Increase Capacity

  2. Fluidigm Obtains CE Mark for Saliva-Based SARS-CoV-2 Assay

  3. Molzym, Fraunhofer Developing Rapid Direct-From-Sample Sepsis Diagnostic Platform and Test

    Premium

  4. Invitae Prices $400M Common Stock Offering

  5. NASA Looking to Spin Out Breath Analysis Platform for Use in Diagnostics Applications

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.